Primary graft failure after umbilical cord blood transplant rescued by parental haplocompatible stem cell transplantation

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 4, 2009, Pages 300-303

  Dvorak, Christopher C ^a   Gilman, Andrew L ^b   Horn, Biljana ^a   Cowan, Morton J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Levine Children's Hospital   (United States)

Author keywords

Graft failure; Haplocompatible stem cell transplantation; Rescue; Umbilical cord blood transplantation

Indexed keywords

CD34 ANTIGEN; CD40 LIGAND;

ACUTE LEUKEMIA; ARTICLE; CASE REPORT; CD40 LIGAND DEFICIENCY; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT FAILURE; HLA MATCHING; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; MALE; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RETREATMENT; T CELL DEPLETION; ADULT; ADULT STEM CELL; CYTOLOGY; GENETICS; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; LEUKEMIA; PARENT; TRANSPLANTATION;

ADULT; ADULT STEM CELLS; CD40 LIGAND; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; LEUKEMIA; MALE; NEUTROPHILS; PARENTS;

EID: 65349176148     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181914a81     Document Type: Article

References (22)

1. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100:1611-1618.
2. Gluckman E, Rocha V, Chevret S. Results of unrelated umbilical cord blood hematopoietic stem cell transplantation. Rev Clin Exp Hematol. 2001;5:87-99.
3. Wall DA, Carter SL, Kernan NA, et al. Busulfan/melphalan/ antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: The Cord Blood Transplantation Study (COBLT) Experience. Biol Blood Marrow Transplantation. 2005;11:637-646.
4. Martin PL, Carter SL, Kernan NA, et al. Results of the Cord Blood Transplantation Study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplantation. 2006;12:184-194.
5. Davies S, Weisdorf D, Haake R, et al. Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994;14: 73-77.
6. Kernan NA, Bordignon C, Heller G, et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. Blood. 1989;74:2227-2236.
7. Chewning JH, Castro-Malaspina H, Jakubowski A, et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplantation. 2007;13:1313-1323.
8. Ohwada C, Nakaseko C, Ozawa S, et al. Second cord blood transplantation (CBT) with reduced-intensity conditioning for graft failure after the first CBT for AML. Bone Marrow Transplant. 2004;34:999-1000.
9. Mizutani E, Narimatsu H, Murata M, et al. Successful second cord blood transplantation using fludarabine and cyclopho-sphamide as a preparative regimen for graft rejection following reduced-intensity cord blood transplantation. Bone Marrow Transplant. 2007;40:85-87.
10. Fernandes J, Rocha V, Robin M, et al. Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation. Br J Haematol. 2007;137:248-251.
11. Chan K, Grimley M, Taylor C, et al. Early identification and management of graft failure after unrelated cord blood transplantation. Bone Marrow Transplant. 2008;42:35-41.
12. Dvorak CC, Steinbach WJ, Brown JMY, et al. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2005;36:621-629.
13. Cortes J, Kantarjian H, O'Brien S, et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer. 1999;85: 1506-1513.
14. Bao L, Sun Q, Lucas K. Rapid generation of CMV pp65-specific T cells for immunotherapy. J Immunother (1997). 2007;30:557-561.
15. Lang P, Mueller I, Greil J, et al. Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. Blood Cells Mol Dis. 2008;40:33-39.
16. Kernan N, Flomenberg N, Dupont B, et al. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation. 1987;43: 842-847.
17. Anasetti C, Amos D, Beatty P, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197-204.
18. Jabbour E, Rondon G, Anderlini P, et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2007;40:431-435.
19. Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol. 2007;25:690-697.
20. Lewalle P, Triffet A, Delforge A, et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant. 2003;31: 39-44.
21. Huang X, Liu D, Liu K, et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/ haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007;92:414-417.
22. Huang X, Liu D, Liu K, et al. Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol. 2008;28:276-283.